Related Experiment Videos
Pharmacogenetic phenotyping and genotyping. Present status and future potential
1Laboratory of Molecular Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Clinical Pharmacokinetics
|January 1, 1994
Summary
Genetic variations in drug-metabolizing enzymes cause significant interindividual differences. Understanding these genetic variations through genotyping can lead to safer and more effective drug administration.
Area of Science:
- Pharmacogenomics
- Biochemistry
Background:
- Interindividual variability in foreign compound-metabolizing enzymes is significant.
- Genetic mutations (null or variant alleles) often explain this variability.
- This variability impacts drug metabolism and disease risk.
Purpose of the Study:
- To explore the role of genetic variability in drug metabolism.
- To highlight the diagnostic potential of genetic testing for metabolism deficiencies.
- To underscore the importance of personalized medicine in drug administration.
Main Methods:
- Biochemical and pharmacological assays for assessing human drug metabolism variability.
- Polymerase chain reaction (PCR) techniques for diagnosing genetic metabolism deficiencies.
- Genotyping and phenotyping tests for evaluating drug metabolism capabilities.
Main Results:
- Genetic differences in enzymes like glutathione S-transferase M1, N-acetyltransferase 2, and CYP2D6 are linked to disease risks (e.g., cancer).
- Genetic deficiencies in enzymes such as CYP2D6 can compromise drug therapy efficacy and safety.
- Variability in enzyme expression is a key factor in individual responses to foreign compounds.
Conclusions:
- Genotyping and phenotyping tests can identify individual drug metabolism capabilities.
- Personalized drug administration protocols can be developed based on genetic profiles.
- Understanding genetic variability in drug metabolism is crucial for optimizing therapeutic outcomes and minimizing adverse drug reactions.